FDA Advisers Back Stronger Roche Holding AG and GlaxoSmithKline's Flu Drug Warnings

GAITHERSBURG, Maryland (Reuters) - U.S health advisers recommended on Tuesday stronger warnings on the labels of flu drugs made by Roche Holding AG and GlaxoSmithKline Plc, amid reports of abnormal and, in the case of the Roche drug, sometimes fatal psychiatric behavior. The U.S. Food and Drug Administration advisory panel reviewed the small but rising number of cases, mostly in Japan, of patients taking Roche's Tamiflu and Glaxo's Relenza who have experienced hallucinations and delirium.